Loading stock…

Albemarle Corporation (ALB) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

ALBAlbemarle

Revenue FY25$5.4B

GROWTH RATING↗

AVERAGE53 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-11%1

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-5%3

EPS growth, FY28E-1%3

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 8%/yr over the next 3 years, ahead of most of the market.7/10

After shrinking over the last 3 years, revenue is set to grow 8%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

WATCH

A mid-pack grower, ahead of 53% of companies worldwide.

WEAKNESSES

Revenue fell 11%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Earnings are set to fall even as revenue grows (EPS about -0.5%/yr vs revenue 8%/yr).

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK5 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-15%1

3-month return-17%2

YTD return-24%2

MID & LONG-TERM▾SCORE

% of 52-week high48%1

1-year return+19%7

3-year return-30%1

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's up 19% over the past year, but 52% below its 52-week high. That is a touch behind the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-30% over three years and -49% over five), behind 90% of the market.

The stock is underperforming over the past month (-15%), over three months (-17%) and so far this year (-24%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Albemarle. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ALBAlbemarle

Revenue FY25$5.4B

GROWTH RATING↗

AVERAGE53 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-11%1

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-5%3

EPS growth, FY28E-1%3

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 8%/yr over the next 3 years, ahead of most of the market.7/10

After shrinking over the last 3 years, revenue is set to grow 8%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

WATCH

A mid-pack grower, ahead of 53% of companies worldwide.

WEAKNESSES

Revenue fell 11%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Earnings are set to fall even as revenue grows (EPS about -0.5%/yr vs revenue 8%/yr).

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK5 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-15%1

3-month return-17%2

YTD return-24%2

MID & LONG-TERM▾SCORE

% of 52-week high48%1

1-year return+19%7

3-year return-30%1

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's up 19% over the past year, but 52% below its 52-week high. That is a touch behind the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-30% over three years and -49% over five), behind 90% of the market.

The stock is underperforming over the past month (-15%), over three months (-17%) and so far this year (-24%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Albemarle. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Albemarle Corporation

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Albemarle. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Albemarle. Get the full investment case.

Premium